Lipodystrophies are a group of ultra-rare disorders of diverse etiology which are characterized by variable loss of body fat.

2. Lipodystrophies are a group of ultra-rare disorders of diverse
etiology which are characterized by variable loss of body fat.
The loss of body fat may affect nearly the entire body
(generalized), only certain body regions (partial) or small areas
under the skin (localized).
Depending upon the severity and extent of body fat loss, patients
may be predisposed to metabolic complications associated with
insulin resistance.
Lipodystrophy major subtypes are Congenital generalized
lipodystrophy, Familial Partial lipodystrophy, Acquired
generalized lipodystrophy, Acquired partial lipodystrophy, and
Localized lipodystrophy.
Lipodystrophy
DelveInsight © 2019 | All rights reserved

3. Lipodystrophy Epidemiology
DelveInsight © 2019 | All rights reserved
Prevalence estimates for 4 major subtypes of
lipodystrophies combined are wide ranging and
varied (approximately 0.1–90 cases/million)
ESTIMATION
PREVALENCE
The global prevalence of lipodystrophy
among HIV-infected adults ranges
considerably less than 1 to 84%.
It is estimated to affect more than 100,000
patients in the United States and greater
numbers elsewhere around the globe.
AFFECTED
PREVALENCE
The genetic lipodystrophies are rare and
estimated prevalence is less than 1 in
1,000,000.

4. Lipodystrophy Market
DelveInsight © 2019 | All rights reserved
01 02 03 04 05
Current therapeutic regimens
for Lipodystrophy metabolic
management consist of
lifestyle modifications such as
diet and exercise.
Lipodystrophy treatment is
primarily focused on
managing the metabolic
abnormalities to prevent
complications.
Companies across the globe
are diligently working
towards the development of
new treatment therapies for
Lipodystrophy treatment.
Although there is no cure for
Lipodystrophy, morbidity and
mortality can be improved
through early intervention.
The expected launch of
emerging therapies in the
late phase of clinical
development, Lipodystrophy
market size is expected to
grow during the forecast
period [2018-2027].

5. Lipodystrophy Emerging Drugs and Companies
DelveInsight © 2019 | All rights reserved
Promising candidates in
the late stages of clinical
development for
Lipodystrophy treatment
are expected to create a
significant impact on
Lipodystrophy market
size.
Drug: Metreleptin
By Aegerion Pharmaceuticals
Drug: Volanesorsen
by Ionis Pharmaceuticals

6. DelveInsight © 2019 | All rights reserved
For complete information on
Lipodystrophy Market Insights, Epidemiology & Market Forecast-2028
please click the link below
CLICK HERE
OR
Write Us At
info@delveinsight.com
Complete Information

7. About DelveInsight
DelveInsight © 2019 | All rights reserved
About
DelveInsight is a premier Business Consulting
and Market Research firm focused exclusively on
the life science segment. With a wide array of
smart end-to-end solutions, the firm helps the
global Pharmaceutical and Bio-Tech companies
formulate prudent business decisions for
improving their performances to stay ahead of
the competitors.
Mission
To provide “insights across the value chain” and
helping the organization to take a prudent
business decision through the use and analysis of
actionable market intelligence. The mission also
is to provide the most effective result and
efficient service with utmost client care for
maintaining a long-term relationship with them.
Vision
To be the most trusted market research & business
consulting firm in the world; and to continue
enable the Pharma & Bio-Tech companies to
achieve their goals with the best strategic insight
and competitive solution. The vision also is
inclusive of becoming a one-stop solution
provider for the entire gamut of drug development
process.
1 2 3

8. Service Offerings by DelveInsight
DelveInsight © 2019 | All rights reserved
OpportunityAssessment
Pipeline
Consulting
MarketIntelligence
Forecasting
ReportStore
Competitive Analysis
PharmDelve

9. Contact Us
DelveInsight © 2019 | All rights reserved
info@delveinsight.com
+91-11-4568 9769
www.delveinsight.com
blog/delveInsight/
twitter/delveInsight
LinkedIn/delveInsight

10. Pompe Disease
9